$0.6219
-0.0333-5.08%
At close: Nov 13, 4:00 PM EST
Calidi Biotherapeutics Inc
CLDIAMEX
Calidi Biotherapeutics fell 97.3% from $24.32 to $0.66, behind the S&P 500's +12.3%. Its worst day was Mar 6 (−53.1%), and its low came Oct 26 at $0.64.
Nov 13, 2025 – Nov 12, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-35.36 missed the $-26.88 estimate on $0.00 revenue.
−1.3% · S&P 500 0.0%
Calidi Biotherapeutics closed at its highest level of the year, 1.3% above where the year started.
Story events cover the past 12 months · Times ET
+2.7% · S&P 500 +0.1%
Calidi Biotherapeutics shares fell 53.1%, while the S&P 500 fell 1.3%.
−53.1%, the year's worst day · S&P 500 −1.3%
EPS of $-9.12 beat the $-24.96 estimate on $0.00 revenue.
−11.7% · S&P 500 −0.3%
EPS of $-6.88 was reported on $0.00 revenue.
−2.3% · S&P 500 −1.2%
EPS of $-2.94 was reported on $0.00 revenue.
+3.2% · S&P 500 −0.2%
Calidi Biotherapeutics closed at its lowest level of the year, 97.4% below where the year started.
−0.8% · S&P 500 +0.7%
Where it ended: a close of $0.66 on Nov 12, 2026. Up next: Q3 2026 earnings on Nov 13, 2026.
Nothing in the past 12 months.
All CLDI analyst actionsNothing in the past 12 months.
All CLDI dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CLDI and SPY from Benzinga historical bars. Not investment advice.
